Testing a New Injection for Graves' Disease
Treatments studied
Part of Eyes & vision, Hormones & metabolism, Immune system & allergy clinical trials.
This study tests efgartigimod, a new medicine given by injection under the skin, to see if it can help control Graves' disease (an overactive thyroid condition). The goal is to reduce the need for other thyroid medications or help people stop taking them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with Graves' disease and have elevated antibodies (TRAb) confirmed at screening
- You currently have an overactive thyroid from Graves' disease, shown by low TSH levels
- You have been taking methimazole or carbimazole (thyroid-controlling drugs) for at least 3 months
- You have not had radioactive iodine treatment or thyroid surgery in the past
- You do not have uncontrolled heart rhythm problems caused by your thyroid condition
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether efgartigimod, an injectable medication given under the skin, can help control overactive thyroid (Graves' disease) in adults already taking methimazole or carbimazole. The goal is to see if it reduces thyroid antibodies and improves thyroid hormone levels.
This trial tests an investigational drug called IMVT-1402 for people with Graves' disease whose thyroid is still overactive even while taking standard antithyroid medication. The goal is to see if the drug can better control thyroid hormone levels.
This trial tests a new drug called IMVT-1402 for adults with Graves' disease whose thyroid is still overactive despite taking antithyroid medication. The goal is to see if the drug can safely help control thyroid hormone levels.
This study tests a new medication called MER511 for adults with Graves' disease. The goal is to see if it is safe and how it works when taken once or multiple times.
This trial tests a new medicine called REGN24493 that may help control Graves' disease by blocking a specific receptor in the body. It is designed for adults who have been diagnosed with Graves' disease and are currently stable on their thyroid levels.
This study tests a new medicine, BHV-1300, to see if it can safely and effectively reduce the overactive thyroid caused by Graves' disease, an autoimmune condition. It may offer a new option for people who haven't had certain prior treatments.
Hear when a new Graves Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.